Asembia AXS26: What the Rise in CGTs Means for the Supply Chain

Key Takeaways

• Reusable shipping containers cut waste and maintain CGT temperature
• Closed‑loop packaging co‑locates manufacturing and distribution to shrink travel distance
• Integrated networks enable 55‑hour delivery, meeting “PDUFA to Patients” goal
• Faster timelines improve patient outcomes and boost therapy adoption rates

Pulse Analysis

The cell and gene therapy (CGT) sector is projected to exceed $30 billion in U.S. sales by 2030, driven by personalized medicines that demand ultra‑cold storage and precise handling. Traditional pharmaceutical logistics, built around bulk, shelf‑stable products, cannot meet the temperature‑sensitive, low‑volume nature of CGTs. As a result, companies are investing in specialized cold‑chain infrastructure, data‑rich monitoring, and end‑to‑end visibility platforms that can guarantee product integrity from manufacturing through infusion.

Sustainability has become a parallel priority. Reusable, multi‑use containers reduce single‑use plastic waste and lower the carbon footprint of temperature‑controlled transport. Cardinal Health’s closed‑loop packaging strategy clusters manufacturing, packaging, and distribution sites within a regional hub, cutting truck miles and associated CO₂ emissions. This model not only aligns with corporate ESG goals but also translates into cost savings through reduced freight rates and streamlined inventory management, creating a competitive advantage for firms that can demonstrate greener operations.

Speed is the third pillar reshaping the CGT supply chain. By integrating logistics functions and leveraging real‑time analytics, providers can compress the interval from regulatory approval to patient infusion to under three days, exemplified by the 55‑hour delivery benchmark. Faster access improves therapeutic efficacy, especially for treatments with narrow therapeutic windows, and enhances payer confidence. As regulators and payers increasingly tie reimbursement to timely delivery, supply‑chain agility will be a decisive factor in the commercial success of next‑generation therapies.